Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$2.1M
Filings
21
Firms Hired
1
Active Period
2017–2021
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 1629
Improving Patient Access to Care and Treatment Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 5950
Improving Patient Access to Care and Treatment Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 5950
Improving Patient Access to Care and Treatment Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 5950
Improving Patient Access to Care and Treatment Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 5950
Improving Patient Access to Care and Treatment Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 5950
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: S250
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: S250
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: S250
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: S250
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: S250
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: S. 3257
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: S. 3257
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: S. 3257
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: S. 3257
A bill to amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: S. 3257
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 1629
Fairness in Orphan Drug Exclusivity Act
2021 · fourth_quarter · Firm: BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC
HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances HR 5950 - Improving Patient Access to Care and Treatment Act S. 3257 - To amend the Controlled Substances Act to lengthen the period of time during which certain controlled substances must be administered to a patient after being delivered by a pharmacy to the administering practitioner.
Client expense: $90,000 · Firm income: —
Matched citations: HR 1629
Source: Senate LDA